The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial

Ludovico Messineo1,2, Kelly Loffler1, Alan Chiang3, Amal Osman1, Luigi Taranto-Montemurro2, Danny J Eckert1

1Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia; 2Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; 3Neuroscience Research Australia, Randwick, NSW, Australia

Correspondence: Ludovico Messineo, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, MA, USA, Email ludovico.messineo@yahoo.it

Rationale: There are widespread histaminergic projections throughout the brain, including hypoglossal nuclei, that modulate pharyngeal muscle tone and respiratory control. Hence, histaminergic stimulation pharmacologically may increase pharyngeal muscle tone and stabilize respiratory control (loop gain) to reduce obstructive sleep apnea (OSA) severity. Antimuscarinics also increase REM pharyngeal muscle tone in rats. Thus, a combination of histaminergic and anti-muscarinic drugs may be a novel target for OSA pharmacotherapy. However, this has not been investigated. Accordingly, we aimed to test the effects of betahistine (Beta), an H3-autoreceptor antagonist which thereby increases histamine levels, in combination with the antimuscarinic oxybutynin (Oxy), on OSA severity, OSA endotypes, polysomnography parameters and next-day sleepiness and alertness.

Methods: Thirty adults with OSA received either Beta-Oxy (96–5mg) or placebo according to a randomized, crossover, double-blind design, prior to polysomnography. Participants completed the Karolinska Sleep Scale and Leeds Sleep Evaluation Questionnaire and a driving simulation task to quantify next-day sleepiness and alertness. OSA endotypes were estimated through validated algorithms using polysomnography.

Results: Compared to placebo, Beta-Oxy increased respiratory control sensitivity (loop gain) (0.52[0.24] vs 0.60[0.34], median [IQR], P = 0.021) without systematically changing OSA severity (34.4±17.2 vs 40.3±27.3 events/h, mean±SD, P = 0.124), sleep efficiency, arousal index or markers of hypoxemia. Beta-Oxy was well tolerated and did not worsen next-day sleepiness/alertness.

Conclusion: Rather than stabilize breathing during sleep, Beta-Oxy increases loop gain, which is likely to be deleterious for most people with OSA. However, in certain conditions characterized by blunted respiratory control (eg, obesity hypoventilation syndrome), interventions to increase loop gain may be beneficial.

Keywords: pharmacotherapy, respiratory control, histamine, sleep disordered breathing, upper airway, endotyping

Plain Language Summary
In light of observations that histaminergic receptors are highly expressed at the hypoglossal level and that antimuscarinics increase pharyngeal muscle tone in REM sleep, we tested the combination of betahistine (Beta), to increase histamine levels, with the antimuscarinic oxybutynin (Oxy) on obstructive sleep apnea (OSA) severity and endotypes. Beta-Oxy increased the sensitivity of the respiratory control system (loop gain) in the absence of an effect on AHI, which makes this combination unsuitable for most OSA patients, but may be promising for disorders characterized by reduced chemosensitivity.

Introduction
Obstructive sleep apnea (OSA) is a common breathing disorder characterized by repetitive narrowing or occlusion of the upper airway during sleep. Impairment in the anatomical components of the upper airway (eg, a narrow/collapsible
pharynx) and other physiological traits/endotypes, such as respiratory control stability/loop gain, the respiratory arousal threshold, and upper airway muscle function, play a major role in mediating the propensity for OSA. Impaired upper airway muscle function or elevated loop gain, via destabilization of upper airway patency and breathing, are estimated to be key pathogenic contributors for more than half of all OSA patients. Current treatments however, such as continuous positive airway pressure (CPAP), mandibular advancement devices, and surgery, primarily target the anatomical endotype, with variable efficacy, compliance and patient outcomes.

Recent research has shown that pharmacotherapy that targets one or more of the non-anatomical OSA endotypes can reduce OSA severity and thus may have a potential future role in personalized treatment for OSA. Key background findings stemmed from animal studies that demonstrated several neurotransmitters play a major role in upper airway stabilization during sleep. Hypoglossal nuclei express abundant concentrations of H1-receptors in rats and guinea pigs. H2-receptors have been identified in the medulla. H3-autoreceptors may also modulate hypoglossal motor-nuclei activity. Histamine administration at the hypoglossal motor nucleus significantly increased tonic (ie, expiratory) activity of the largest upper airway dilator muscle, genioglossus, in both non-REM and REM sleep via activating H1-receptors in rats and cats. However, histamine neurons become largely silent at sleep onset during natural sleep. In humans, knowledge on the role of histaminergic stimulation on upper airway stability is limited. Desipramine, which reduced upper airway collapsibility in healthy controls and OSA patients, had minimal effects on the AHI overall, likely due to a wide, non-specific spectrum of target activity, including antagonism of histaminergic receptors. Pitolisant, an H3-autoreceptor inverse agonist with wake promoting properties, increases daytime alertness in people with OSA. However, the effects of histaminergic mechanisms on upper airway stability and respiratory control in people with OSA have not been investigated.

Betahistine, a drug commonly used in clinical practice for Ménière syndrome, is a mild H1-agonist and a potent H3-autoreceptor antagonist/inverse agonist. H3-autoreceptor blockage increases brain levels of histamine. Additionally, H3 antagonism can potentiate the activity of other neurotransmitters in the central nervous system, including norepinephrine, highly expressed at the hypoglossal motor nuclei, and acetylcholine.

Recent studies indicate that noradrenergic agents, which, like histamine agonists, also have wake promoting properties, can reduce OSA severity when combined with an antimuscarinic. An antimuscarinic would be an ideal candidate to combine with histamine for several reasons: 1) animal data suggest that antimuscarinics directly increase pharyngeal muscle tone during REM sleep; 2) antimuscarinics also have mild sleep promoting effects and this property may be beneficial to counteract, at least in part, the wake promoting properties of other agents (such as betahistine in the current work) when used in combination therapy for OSA; 3) an antimuscarinic may offset H3-mediated cholinergic stimulation effects.

In this randomized, double-blinded, placebo controlled, crossover study we aimed to investigate the effects of betahistine combined with the antimuscarinic oxybutynin (Beta-Oxy) on OSA severity (primary outcome). This previously untested combination of theoretically synergic drugs may provide insight into new treatment targets for OSA. Secondary outcomes were to investigate the effects of the combination on OSA endotypes, other standard polysomnography parameters and next-day sleepiness and alertness.

**Methods**

**Participants**

Thirteen people with a diagnosis of OSA within the past year (apnea/hypopnea index [AHI] >15 events/hr) aged 18 to 75 years were recruited. Participants on CPAP therapy were asked to suspend treatment during the trial and for one week prior to the first study visit. Exclusion criteria included any acute or chronic condition other than controlled hypertension and hypercholesterolemia; hypersensitivity to the study drugs; class 3 obesity; any medication known to influence breathing, sleep/arousal, muscle physiology, or to interact with mono amino oxidases; and current treatment with tricyclic antidepressants.

The study was approved by the Southern Adelaide Clinical Research Ethics Committee (248.20), a joint committee of the Southern Adelaide Local Health Network and Flinders University, was prospectively registered (ACTRN12621000158864).
and was performed in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent prior to enrolment. Participants studied at Adelaide Institute for Sleep Health, Flinders University.

Protocol

Participants were asked to come to the sleep laboratory twice, one week apart, to undertake two overnight sleep studies. Prior to lights-out (based on the participant’s usual bedtime and kept constant between study nights), participants received 96 mg betahistine plus 5mg oxybutynin or placebo according to a double-blind, randomized, crossover design (Figure 1). The study pharmacist, separate to the study site, provided the randomization code and maintained allocation concealment throughout the study. Study medications were placed in identical capsules that could not be identified by study personnel or participants. Prior to sleep, participants were instructed to sleep on their back as much as possible and were given a standardized 8-hour sleep opportunity during each study visit.

Participants slept with standard clinical polysomnography equipment including a nasal cannula attached to a pressure transducer to estimate airflow. On the first night, ~30 mins after arrival, participants completed the Insomnia Severity Index and the Epworth Sleepiness Scale questionnaires. Systemic blood pressure and the Karolinska Sleepiness Scale (KSS) were recorded during both visits, ~30 min before bed and ~30 min after wake time. In addition, participants completed a 30-minute alertness test using the AusEd driving simulator and the Leeds Sleep Evaluation Questionnaire (LSEQ) during the next

morning following each study night. Potential side effects (eg, dry mouth, dysuria, etc.) were also investigated in the morning after each sleep study and on arrival back to the laboratory after the one-week washout period.

Data Analysis
All analyses were conducted blinded to the study interventions. Respiratory events and arousals were scored using standard American Academy of Sleep Medicine 2020 criteria.36 OSA endotypes (ie, loop gain, arousal threshold, upper airway collapsibility (V\text{passive}), markers of pharyngeal muscle compensation (V\text{active} and V\text{comp}) and the ventilatory response to arousal) were estimated from the polysomnography-derived flow signal using previously validated algorithms.37–39 In brief, loop gain was calculated as the response to disturbance of different frequencies: one cycle/minute (ie, loop gain\textsubscript{1}) and the frequency that would lead to periodic breathing onset (ie, loop gain at natural frequency [loop gain\textsubscript{n}]). Arousal threshold was calculated as the average estimated ventilation during sleep prior to arousals (ie, maximum ventilatory drive). V\text{passive} was defined as the ventilation during sleep at eupneic ventilatory drive when the pharyngeal muscles are relatively passive. V\text{active} was defined as the level of ventilation at maximum drive (ie, arousal threshold). V\text{comp} was taken as the difference between ventilation at maximal drive and as an estimate of pharyngeal muscle compensation. All traits, except for loop gain, which is dimensionless, were expressed as percent of the estimated eupneic ventilation (V\text{eupnea}).

Statistical Analysis
An a priori power calculation indicated that 12 participants were required to detect a minimally important change in AHI of 10 events/hour (SD = 10) with >80% power at an alpha level = 0.05 (two-tailed paired t-test), allowing for a 20% drop-out rate. Continuous data were expressed as mean±SD, or median [interquartile range] for non-normally distributed data. Statistical significance was inferred if \(p<0.05\). According to our statistical analysis plan, data were analyzed using two-tailed paired Student’s t-tests or a Wilcoxon signed-rank test as appropriate. A mixed model analysis was also carried out (random effect: participants; fixed effects: treatment and percent supine sleep) to explore potential effects of sleep positions on the AHI (effect size [confidence interval]). Exploratory linear regression assessed the association between baseline loop gain and change in AHI between the nights. Analyses were performed using Graph Pad Prism 6.0 (Graph Pad Software, La Jolla, CA) and SPSS 23.00 (IBM, Armonk, NY).

Results
Thirteen participants were recruited to allow for a potential drop out to reach our recruitment target of \(n = 12\). However, all 13 participants successfully completed both nights and were included in the analyses (Figure 1). Baseline participant characteristics are shown in Table 1. Participants were recruited from October 2020 to May 2021.

Effect of Beta-Oxy on OSA Severity
Beta-Oxy did not systematically alter OSA severity versus placebo (Figure 2), including when separated according to sleep stage (Table 2). The supine AHI also did not change between study nights (51.0±22.8 on placebo versus 51.0±31.1 events/h on Beta-Oxy, \(P = 0.37\)). When adjusting for sleeping body position (Table 2) and missing values in the supine position (in \(N = 2\) nights there was no recorded supine sleep data), there was no effect of the combined drugs on OSA severity (AHI: +6.33 [−0.93, 13.60] events/h, mean [CI], \(P = 0.08\)). Overnight desaturation profiles were also not significantly different between the two treatment arms (Table 2).

Effect of Beta-Oxy on OSA Endotypes
Beta-Oxy significantly increased loop gain\textsubscript{1} compared to placebo (Table 3). Loop gain\textsubscript{n} was also greater on Beta-Oxy versus placebo in all but one of the study participants (Figure 3). The other OSA endotypes did not change between nights (Table 3). Notably, the change in AHI between the nights was directly associated with loop gain on the placebo night such that OSA severity increased in those with higher loop gain values (Figure 4).
Beta-Oxy changed sleep architecture as reflected via an increase in N1 sleep versus placebo (Table 2). No other significant differences were detected between nights for overall sleep efficiency, total sleep time, wake after sleep onset or arousal index (Table 2).

Beta-Oxy did not change next-day sleepiness or alertness according to KSS, LSEQ scores or to the AusEd driving simulation task versus placebo (Table 4). Overall, the drug combination was well tolerated. Three participants had minor complaints following study visits. One participant reported vertigo and visual aura in the morning following the Beta-Oxy night, another reported a longer than usual menstrual phase on return to the laboratory during the washout week following the placebo night.

Three participants reported feeling rested/wide awake after Beta-Oxy single-night treatment versus one after placebo (P = 0.194). Similarly, only one participant reported feeling very tired after Beta-Oxy versus three participants after the placebo night (P = 0.139). Four participants on Beta-Oxy versus six on placebo felt that the corresponding laboratory night was worse/much worse than sleeping at home (P = 0.619). Perceived sleep latency was comparable between placebo and Beta-Oxy (29±18 min v. 44±60 respectively, P = 0.397).

**Table 1 Baseline Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>61±6</td>
</tr>
<tr>
<td>Sex, M:F</td>
<td>6:7</td>
</tr>
<tr>
<td>Neck circumference, cm</td>
<td>39.1±3.9</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>106.9±17.3</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>31.1±5.2</td>
</tr>
<tr>
<td>Mallampati index</td>
<td>3±1</td>
</tr>
<tr>
<td>Insomnia severity index</td>
<td>11±5</td>
</tr>
<tr>
<td>Epworth sleepiness scale</td>
<td>7±4</td>
</tr>
</tbody>
</table>

*Note: Data are mean ± standard deviation, or counts for sex.*

**Effect of Beta-Oxy on Other Polysomnography Parameters, Next-Day Sleepiness and Alertness, and Safety**

Beta-Oxy changed sleep architecture as reflected via an increase in N1 sleep versus placebo (Table 2). No other significant differences were detected between nights for overall sleep efficiency, total sleep time, wake after sleep onset or arousal index (Table 2).

Beta-Oxy did not change next-day sleepiness or alertness according to KSS, LSEQ scores or to the AusEd driving simulation task versus placebo (Table 4). Overall, the drug combination was well tolerated. Three participants had minor complaints following study visits. One participant reported vertigo and visual aura in the morning following the Beta-Oxy night, another reported a longer than usual menstrual phase on return to the laboratory during the washout week following the placebo night.

Three participants reported feeling rested/wide awake after Beta-Oxy single-night treatment versus one after placebo (P = 0.194). Similarly, only one participant reported feeling very tired after Beta-Oxy versus three participants after the placebo night (P = 0.139). Four participants on Beta-Oxy versus six on placebo felt that the corresponding laboratory night was worse/much worse than sleeping at home (P = 0.619). Perceived sleep latency was comparable between placebo and Beta-Oxy (29±18 min v. 44±60 respectively, P = 0.397).

![Figure 2](https://doi.org/10.2147/NSS.S362205) There was no systematic difference in apnea-hypopnea index (AHI) between study nights (34.4±17.2 vs 40.3±27.3 events/h sleep, P = 0.124). Bars represent mean ± standard deviation.
This is the first proof-of-concept, mechanistic study to investigate the effects of a histaminergic agent, together with an anti-muscarinic, on OSA severity in humans. Beta-Oxy led to a physiologically important increase in loop gain, without changing the AHI, other sleep parameters or next-day sleepiness/alertness. These findings provide novel physiological insight and, if confirmed in larger follow-up studies, may have implications for certain respiratory diseases where blunted respiratory control is a feature.
Figure 3 Beta-oxy significantly increased loop gain at the natural frequency of resonance (loop gain\textsubscript{n}) by a physiologically meaningful margin (>10%; Δchange = 0.06±0.05 [mean±SD], P = 0.001, asterisk).

Figure 4 Relationship between change in apnea-hypopnea index (AHI) and loop gain (placebo visit). Change in AHI and loop gain\textsubscript{n} (upper panel) and loop gain\textsubscript{n} (lower panel) is illustrated. Individual participants are indicated by dots and solid line indicates the calculated relationship from linear regression.
Novel Physiological Insights
The response to a respiratory disturbance during sleep (reduced ventilation) consists of an accumulation of ventilatory drive that generally matches increased hypoxic—and hypercapnic—demand to generate a subsequent ventilatory compensation response. The main effectors of this process, a constituent component of loop gain, are the chemoreceptors, that project to the nucleus tractus solitarii in the brainstem and are influenced via a wide supply of neurotransmitters, including histamine. In rats, histaminergic modulation through H1-receptor stimulation or H3-receptor blockade in the brain, augments chemoreflex control. A similar effect was observed in goats and cats. However, its human translatability was only putative. This study shows that loop gain is almost invariably increased with Beta-Oxy in people with OSA, indicating that this potent chemosensitivity excitatory modulation is also present in humans during sleep.

Conversely, it is not clear why Beta-Oxy did not have an effect on estimated pharyngeal muscle compensation despite the strong neurobiological rationale behind our study hypothesis. One explanation could be that the dose of betahistine was not high enough to produce a detectable effect on this endotype. 96 mg was selected in this study as it is twice as high as a typical dose administered clinically, although up to 200 mg was well tolerated in other studies with no significant complications. A second explanation is that betahistine did lead to an increase in genioglossus muscle activity (not directly measured in this study) but its potential beneficial effect on OSA was offset by the more pronounced increase in loop gain and thus was not detectable via our indirect measurement technique. Indeed, \( V_{\text{comp}} \) is the most challenging endotype to accurately quantify using polysomnography-based estimates. Accordingly, it will be important in future studies to directly measure pharyngeal muscle activity, including different doses, to investigate the effects of betahistine definitively.

Clinical and Physiological Implications
A drug that increases loop gain without altering pharyngeal pathophysiology could have disparate effects in clinical practice. The prokinetic domperidone has been shown to increase chemosensitivity and loop gain in animal models and early reports in healthy humans. However, this effect is presumably only mediated at the peripheral chemoreceptors as domperidone poorly penetrates the blood brain barrier. Betahistine could exert its effects on either central or peripheral chemoreceptors, and this may unveil therapeutic implications for conditions in which central chemosensitivity is impaired or depressed, such as obesity hypoventilation syndrome, congenital central hypoventilation and opioid-induced respiratory depression. Thus, the use of betahistine in these conditions is worthy of further investigation in light of the current novel findings on respiratory control.

Conversely, although there was no overall increase in AHI in the current study, any agent that increases loop gain in people with OSA where blunted respiratory control is not a feature, especially in the more than one-third of patients who

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo</th>
<th>Beta-Oxy</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karolinska sleepiness scale</td>
<td>6±1</td>
<td>5±2</td>
<td>0.180</td>
</tr>
<tr>
<td>Leeds Sleep Evaluation Questionnaire</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Getting to sleep</td>
<td>5.0±0.7</td>
<td>5.0±1.18</td>
<td>0.984</td>
</tr>
<tr>
<td>Quality of sleep</td>
<td>4.5±1.8</td>
<td>4.5±1.4</td>
<td>0.889</td>
</tr>
<tr>
<td>Awake following sleep</td>
<td>4.3±1.3</td>
<td>5.2±1.2</td>
<td>0.079</td>
</tr>
<tr>
<td>Behavior following sleep</td>
<td>4.2±1.2</td>
<td>4.4±1.1</td>
<td>0.647</td>
</tr>
<tr>
<td>AusEd driving simulator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deviation from median of lane, cm</td>
<td>39.5±27.6</td>
<td>38.7±19.9</td>
<td>0.932</td>
</tr>
<tr>
<td>Deviation from 60–80 km/h, km/h</td>
<td>0.5±2.0</td>
<td>0.7±1.6</td>
<td>0.952</td>
</tr>
<tr>
<td>Breaking time, s</td>
<td>1.0±0.3</td>
<td>1.1±0.3</td>
<td>0.503</td>
</tr>
<tr>
<td>Crashes, n</td>
<td>0±1.0</td>
<td>0±0.5</td>
<td>0.937</td>
</tr>
</tbody>
</table>

Notes: Data are mean ± standard deviation or median [interquartile range]. Conditions were compared with a two-tailed paired Student’s t-test.
already have high loop gain,\(^2\) is likely to be deleterious. Our finding that Beta-Oxy was associated with increased OSA severity in participants with high loop gain on placebo and vice versa provides initial support for this concept. Thus, the use of betahistine in most people with OSA should be cautioned until further endotype-specific studies are performed to separate out the characteristics of those who may experience beneficial versus deleterious effects.

Despite well-known histamine-related arousal facilitation,\(^5,7\) Beta-Oxy did not worsen sleep efficiency or increase the arousal index or the arousal threshold. However, there was a small increase in lighter N1 stage sleep. While these findings may provide support that betahistine (widely used worldwide at any time of the day) is unlikely to disrupt sleep, it may also be that potential sleep disruption effects were alleviated by oxybutynin which can serve as a mild sleep promotion aid.\(^4,6,31–33\) This will require further investigation with betahistine studied in isolation rather than in combination with oxybutynin.

**Methodological Considerations**

This study has several limitations. 1) As highlighted, betahistine and oxybutynin were not tested separately, and we cannot, therefore, confidently discriminate the effects of the single drugs. However, when studied in a single drug trial, oxybutynin alone did not increase loop gain.\(^4\) Thus, the effect on loop gain observed in this study is likely to be solely attributable to the increase in histaminergic tone. 2) Due to the clinical setting of the polysomnography studies, we did not record end-tidal CO\(_2\) and the different components of loop gain (eg, plant gain, controller gain) were not calculated. Also, tidal volume was not recorded. Yet, based on the neurobiological signaling attributed to H3-receptor blockade from animal data, betahistine effects on loop gain are likely to be predominantly mediated by increased chemosensitivity (controller gain). 3) We also did not assess whether the histaminergic mediated changes took place in the central, peripheral chemoreceptors or both. 4) All endotypes were collected using polysomnography-derived signals that provide estimates of gold-standard measurements. As highlighted, the current findings provide initial physiological insight to guide future more detailed physiological research investigations.

**Conclusions**

The combination of betahistine, a histaminergic drug, and the antimuscarinic oxybutynin increases loop gain in people with OSA, without major accompanying systematic effects on OSA severity, sleep architecture or next-day alertness and sleepiness.

**Data Sharing Statement**

Trial protocol and data will be stored for up to 15 years and will be available after de-identification upon request and subject to ethical approval. Data sharing requests should be directed to Danny Eckert: aish.sleeplab@flinders.edu.au.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This study was funded by a National Health and Medical Research Council (NHMRC) of Australia Investigator Grant (1196261). DJE is also supported by a NHMRC Senior Research Fellowship (1116942).

**Disclosure**

Alan Chiang reports grants from Cooperative Research Centre Project Grant (Australian Government, Academia and Industry collaboration, Industry partner: Oventus Medical), outside the submitted work. Luigi Taranto-Montemurro is Chief Scientific Officer of Apnimed and has a financial interest in Apnimed, a company developing pharmacologic therapies for sleep apnea. His interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies; and reports personal fees from Apnimed,
outside the submitted work. Danny J Eckert reports grants from National Health and Medical Research Council of Australia, during the conduct of the study; research grants and personal fees from Bayer, Apnimed, Takeda, and Invicta Medical, and a Collaborative Research Centre (CRC-P) Consortium Grant between the Australian Government, Academia and Industry (Industry partner: Oventus Medical) and serves on the Scientific Advisory Boards for Invicta Medical and Apnimed, outside the submitted work. The authors report no other potential conflicts of interest in relation to this work.

References


